SV Life Sciences
ActiveFiled to raiseLondon, X0Healthcare, Biotechnology, PharmaceuticalsLast fund filed December 2025
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| SV8 Biotech Fund | December 2025 | Indefinite | $70M | 3 |
| SV7 Plus Growth FundFiled to raise in 2024, with no closing reported yet. | 2024 | $60M | $0 | 0 |
| Dementia Discovery Fund 2 | March 2022 | $350M | $202M | 16 |
| SV7 Growth Fund Strategic PartnersFiled to raise in 2022, with no closing reported yet. | 2022 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
19 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael RossNot on the current fund | Selective | Biotech & pharma, Digital health, Food & agriculture | 23 |
Classified sectors of SV Life Sciences’s own portfolio companies, based on 70 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Virtuoso-mccarran | 23 | 20/20 GeneSystems, AmeriClean Holdings, Andovia, Arsanis, Avitide, CATABASIS PHARMACEUTICALS, CERVILENZ, Deciphera Pharmaceuticals, Dualitas Therapeutics, Euclid Systems, everee, Eyebiotech, FRESCO FOODS, Healthcare Solutions Holdings, Maine Crisp Company, NICE Recovery Systems, Ophthotech, Ribometrix, SUTRO BIOPHARMA, Therini Bio, THESAN PHARMACEUTICALS, TRex Holdings, Xilio Therapeutics |
| New Leaf | 3 | CARDIOKINETIX, Direct Flow Medical, Reshape Medical |
| Polaris Partners | 3 | Arsanis, QurAlis, TRex Holdings |
| SV Biotech Crossover Opportunities Fund |
| December 2021 |
| $350M |
| $135M |
| 7 |
| SV Life Sciences Fund IV CF | August 2021 | $421M | $421M | 44 |
| SV7 Growth Fund | September 2019 | $250M | $91M | 12 |
| SV7 Impact Medicine FundFiled to raise in 2019, with no closing reported yet. | 2019 | $250M | $0 | 0 |
| SV Life Sciences Fund VI Strategic Partners | March 2017 | $13M | $13M | 35 |
| Dementia Discovery | October 2015 | $302M | $26M | 3 |
| SV Life Sciences Fund VI | May 2015 | $400M | $274M | 24 |
| 3 |
| Paul LaVioletteNot on the current fund | Slowing | Medical devices, Biotech & pharma, Digital health | 18 | 1 |
| - SV Health Managers LLP | Quiet | None listed | 0 | 0 |
| Catherine BinghamNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| Christian JungNot on the current fund | Quiet | None listed | 0 | 0 |
| David MilneNot on the current fund | Quiet | Medical devices, Robotics & hardware, Digital health | 10 | 0 |
| Eugene HillNot on the current fund | Quiet | Healthcare services | 2 | 0 |
| Greg MaddenNot on the current fund | Quiet | Medical devices, Biotech & pharma, Climate & energy | 7 | 0 |
| Hamish CameronNot on the current fund | Quiet | None listed | 0 | 0 |
| Houman AshrafianNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| James Costine | Quiet | Biotech & pharma | 1 | 0 |
| James GarveyNot on the current fund | Quiet | Medical devices, Fintech | 3 | 0 |
| Jonathan BehrNot on the current fund | Quiet | Biotech & pharma | 6 | 0 |
| Kate Bingham | Quiet | None listed | 0 | 0 |
| Laurence BarkerNot on the current fund | Quiet | Biotech & pharma | 2 | 0 |
| Michael BalmuthNot on the current fund | Quiet | Aerospace & defense, AI & machine learning, Digital health | 5 | 0 |
| Nicola TrbovicNot on the current fund | Quiet | None listed | 0 | 0 |
| Tetsuyuki MaruyamaNot on the current fund | Quiet | None listed | 0 | 0 |
| Thomas FlynnNot on the current fund | Quiet | None listed | 9 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of SV Life Sciences’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 82vs | 2 | Arsanis, Avitide |
| GTP AW | 2 | Arsanis, Avitide |
| U.S Venture Partners | 2 | CARDIOKINETIX, Reshape Medical |
| 7wire Ventures | 1 | CLARIFY MEDICAL |
| Adams Street | 1 | QurAlis |
| Aisling Capital | 1 | TRANSENTERIX |
| Arboretum Ventures | 1 | CERVILENZ |
| Atlas Venture | 1 | Xilio Therapeutics |
| Bain Capital Life Sciences | 1 | Xilio Therapeutics |
| BCV | 1 | ImmunoMolecular Therapeutics |
| Borealis | 1 | Avitide |
| Caduceus Capital | 1 | Arsanis |
A shared board seat: a company where filings name a SV Life Sciences partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.